Aldeyra shares spiral after a late-stage failure in dry eye disease — but that won't stop its pursuit of an NDA

Nicole DeFeudis

Editor

Aldeyra Therapeutics’ shares tanked in premarket trading after the company admitted its dry eye candidate reproxalap missed the primary endpoint in a topline Phase III …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aldeyra shares spiral after a late-stage failure in dry eye disease — but that won't stop its pursuit of an NDA

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Aldeyra shares spi­ral af­ter a late-stage fail­ure in dry eye dis­ease — but that won't stop its pur­suit of an NDA

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Aldeyra shares spiral after a late-stage failure in dry eye disease — but that won't stop its pursuit of an NDA